45th week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210346439 | LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTION - The use of a bacterium of the species | 2021-11-11 |
20210346440 | COMPOSITIONS AND METHODS FOR REDUCING BLOOD ALCOHOL CONTENT - Disclosed are compositions and methods for reducing blood alcohol content following alcohol consumption. The inventive compositions and methods rapidly reduce blood alcohol content and alleviate symptoms of intoxication in a subject having an elevated blood alcohol content due to alcohol consumption. | 2021-11-11 |
20210346441 | NON-REPLICATING VIRUS-DERIVED PARTICLES AND USES THEREOF - There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties. | 2021-11-11 |
20210346442 | WATER-SOLUBLE, FULL-SPECTRUM, CANNABIS COMPLEX AND METHOD OF PRODUCTION - Disclosed herein is a process of producing a water-soluble solid including an amino acid-cyclodextrin-cannabinoid complex from extraction of | 2021-11-11 |
20210346443 | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same - The present invention relates to a composition and methods comprising an amount of β-glucans and α-fucans, wherein the combination is synergistic to at least one of: increase growth of beneficial microbes and reduced levels of harmful microbes selected from | 2021-11-11 |
20210346444 | USE OF NELUMBO NUCIFERA LEAF EXTRACT IN PREPARING A PHARMACEUTICAL COMPOSITION FOR THE INCREASE OF ADULT HIPPOCAMPAL NEUROGENESIS - The present invention provides a composition comprising | 2021-11-11 |
20210346445 | INFUSED CANNABIS PRODUCT SYSTEM AND METHOD - A method of producing a | 2021-11-11 |
20210346446 | WATER SOLUBLE CANNABINOID BEVERAGE COMPOSITION - A beverage syrup containing cannabinoids can be prepared by solubilizing insoluble cannabinoids in a diluent having dispersion surfactant properties. The diluent can be prepared by mixing a solvent having surfactant properties, such as polysorbate 80, with a co-surfactant, such as propylene glycol. Solid cannabinoids can solubilized by heating the solid concentrate to liquefying it, and then adding the liquid concentrate to the prepared diluent. The resulting syrup can be stored for use in the manufacture of beverages. | 2021-11-11 |
20210346447 | Compositions and Methods for Joint Health - Compositions for and methods of maintaining bone structure, cartilage structure or both, minimizing bone reabsorption, preventing cartilage degradation, increasing bone density, promoting healthy joints by protecting cartilage integrity, diminishing the action of enzymes that affect bone health, cartilage health, or both, improving joint movement or function, alleviating joint pain, alleviating joint discomfort, alleviating joint pain and discomfort, alleviating joint stiffness, improving joint range of motion or flexibility, promote mobility, or the like, wherein the composition comprises a therapeutically effective amount of a botanical extract of the testa of | 2021-11-11 |
20210346448 | THERAPY FOR PROMOTING CELL GROWTH - There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells. | 2021-11-11 |
20210346449 | EXTRACTS OF MORICANDIA FOR THE USE THEREOF IN THE PREVENTION AND TREATMENT OF METABOLIC DISEASES - A composition including an extract of | 2021-11-11 |
20210346450 | COMPOSITION COMPRISING HERBAL EXTRACTS - A composition for treating skin disorders including a mixture of herbal extracts of | 2021-11-11 |
20210346451 | CHINESE MEDICINE COMPOSITION AND PREPARATION METHOD AND USE THEREOF - Technologies relating to Chinese medicine composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of patients are disclosed. An example composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of a patient, includes: an | 2021-11-11 |
20210346452 | TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING TUMOURS, PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a traditional Chinese medicine composition for treating tumours and a preparation method therefor, wherein the composition is prepared from | 2021-11-11 |
20210346453 | COMPOSITIONS AND METHODS FOR TREATMENT OF COVID-19 - The present disclosure relates generally to methods for treating coronavirus infections (e.g., SARS-CoV- | 2021-11-11 |
20210346454 | Botanical Antioxidants - A botanical extract that exhibits antioxidant activity, wherein the botanical extract is at least an extract from the genus | 2021-11-11 |
20210346455 | PHARMACEUTICAL COMPOSITION COMPRISING PURPLE CORN EXTRACT FOR PREVENTION OR TREATMENT OF SKIN DISEASE - Disclosed are a pharmaceutical composition for preventing or treating a skin disease containing a purple corn extract, and more particularly, to a pharmaceutical composition for preventing or treating a skin disease containing a purple corn extract that has a potent effect of preventing or treating at least one skin disease selected from the group consisting of atopy, psoriasis, eczema, keratosis, prurigo and warts, using the purple corn extract. | 2021-11-11 |
20210346456 | MULTIFUNCTIONAL FORMULATION COMPRISED OF NATURAL INGREDIENTS AND METHOD OF PREPARATION/MANUFACTURING THEREOF - This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phyto-pharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment. | 2021-11-11 |
20210346457 | COMPOSITIONS COMPRISING CANNABINOIDS AND PHYTOCHEMICALS, AND USES THEREOF - The present application relates to compositions comprising cannabidiol and at least one phytochemical compound. The at least one phytochemical may be selected from Guggul extract ( | 2021-11-11 |
20210346458 | COMPOSITIONS AND METHODS FOR IMPROVING BRUISING AND REJUVENATING SKIN - Compositions and methods for improving bruising, stimulating elastin and/or collagen production, stimulating intrinsic hyaluronic acid production, stimulating adipogenesis, reducing inflammation, or combinations thereof are provided herein. Compositions and methods described herein may be used following a cosmetic procedure. | 2021-11-11 |
20210346459 | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs - The proposed method is related to pharmaceutics and medicine and concerns applications of Dalargin solution and compositions based on Dalargin in a spray form for irrigation of the oral cavity and nasopharynx and in the inhalation form using a nebulizer for prevention of viral respiratory infections or for the prevention of complications thereof, especially in early stages of the disease. The method describes characteristics of the composition of an inhalation solution having high efficiency for inhalation therapy for prophylaxis of acute respiratory viral infections or the prevention of complications of viral respiratory infections. A detail description of particular techniques and examples of carrying out the method are provided. | 2021-11-11 |
20210346460 | TREATMENTS FOR COVID-19-RELATED SYSTEMIC SCLEROSIS, VASCULAR INSUFFICIENCY, DISTAL ISCHEMIA, AND RELATED DISEASE CONDITIONS - A medical composition for treatment of a peripheral vascular disease is provided. The medical composition may include a dosage of a GABA-a agonist, a dosage of an Angiotensin II modulator, and a dosage of a Direct Oral Anticoagulant. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, the ARB being an Angiotensin II, type 1 receptor antagonist. A method for treating a patient with a microvascular disease condition is provided. The patient may be provided, the medical composition may be provided, and the medical composition may be administered. The step of providing the patient may include providing a patient with at least one of systemic sclerosis, vascular insufficiency, distal ischemia, COVID-19 infection, and sepsis. | 2021-11-11 |
20210346461 | UTILIZATION OF ENDOGENOUS OUBAIN-REGULATING COMPOUNDS AND COMPOSITIONS THEREOF IN TREATMENT OF VASCULAR DISEASE - A method for treating a patient with a vascular disease condition by improving blood flow is provided. The method may include providing the patient with a vascular disease condition; testing a level of EO in the patient; determining, based on the tested level and a threshold level, that EO up-regulation (or EO down-regulation) would facilitate increased Prostacyclin release; providing a medical composition; and administering the medical composition to the patient. The medical composition may include a first dosage of a GABA-a agonist, a second dosage of an Angiotensin II modulator, and a third dosage of at least one EO-regulating compound. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, the ARB being an Angiotensin II, type 1 receptor antagonist. The at least one EO-regulating compound may be effective to up-regulate (or down-regulate) EO in blood vessels affected by the vascular disease condition. A medical composition is also provided. | 2021-11-11 |
20210346462 | METHODS OF REDUCING TYPE 2 CYTOKINE-MEDIATED INFLAMMATION USING NEUROMEDIN PEPTIDES - Methods are provided for reducing type 2 cytokine-mediated inflammation, for example by reducing IL-5 and Il-13 activity, using native and variant neuromedin B (Nmb) peptides or coding sequences. Such methods can be used to treat an inflammatory disorder, such as asthma, COPD or an allergic reaction. Also provided are modified Nmb peptides. | 2021-11-11 |
20210346463 | COMPOSITIONS AND METHODS FOR ENHANCING SYSTEMIC DELIVERABILITY, TOLERABILITY, AND EFFICACY OF CATIONIC MACROCYCLIC PEPTIDES - Compositions are provided for formulations of θ-defensin and/or a θ-defensin analog that are highly suitable for parenteral administration. Such formulations provide the θ-defensin and/or a θ-defensin analog in a slightly acidic buffer that includes propylene glycol. Surprisingly, Inventors have found that such formulation increase bioavailability of a θ-defensin and/or a θ-defensin analog so provided by at least a factor of 10 relative to conventional isotonic saline solutions, and that such formulations dramatically improved bioavailability in human subjects relative to animal models. Inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, reducing injection volume permitting sterilization by simple filtration. | 2021-11-11 |
20210346464 | TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS - Provided herein are methods for treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes in subjects with ring sideroblasts by subcutaneous administration of an ActRIIA or ActRIIB ligand trap. | 2021-11-11 |
20210346465 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2021-11-11 |
20210346466 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2021-11-11 |
20210346467 | COMPOSITIONS AND METHODS FOR INHIBITING THE BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES - The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful. | 2021-11-11 |
20210346468 | AMYLIN ANALOGUES - The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation. | 2021-11-11 |
20210346469 | Compositions and Methods for Increasing Insulin Sensitivity - Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin. | 2021-11-11 |
20210346470 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORAL DISEASES - Methods for the prevention and treatment of oral cavity diseases caused by dental plaque/biofilm, such as dental caries, gingivitis and periodontitis, through anti-infective properties are disclosed. The methods use a combination of EDTA and citrate. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in polymicrobial dental biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, spray, or other suitable form. | 2021-11-11 |
20210346471 | SUPEROXIDE DISMUTASE COMPOSITIONS AND METHODS - The present disclosure is drawn to superoxide dismutase (SOD) compositions and methods thereof. A topical composition can comprise a combination of a therapeutically effective amount of superoxide dismutase (SOD) with a stabilizing carrier that is suitable for topical administration. A method of treating a condition in a subject that is responsive to treatment with superoxide dismutase (SOD) can comprise administering a therapeutically effective amount of the topical composition. A method of stabilizing a superoxide dismutase (SOD) composition can comprise combining an amount of SOD with deoxygenated water to form an SOD solution, and minimizing exposure of the SOD solution to reactive oxygen species (ROS). | 2021-11-11 |
20210346472 | NANOREACTOR USING POLYION COMPLEX POLYMERSOMES, AND METHOD FOR PRODUCING SAME - The present invention provides a nanoreactor (nano size reaction field) using a polyion complex polymersome and a method for producing the nanoreactor. The present invention provides a polyion complex polymersome encapsulating e.g., an enzyme, in which the enzyme is an enzyme acting on a substance passing through a membrane of the polyion complex polymersome, as a substrate. | 2021-11-11 |
20210346473 | ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM - A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease. | 2021-11-11 |
20210346474 | MASPIN, MASPIN DERIVATIVES, AND MASPIN MIMETICS FOR REDUCING ROS, INFLAMMATION, AND SKIN AGING - The present invention provides compositions, methods, and systems for treating inflammatory conditions (e.g., by inhibiting reactive oxygen species) in or on a subject with maspin, maspin derivatives, or maspin mimetics. In some embodiments, such agents are applied to the skin of a subject (e.g., to reduce skin aging). | 2021-11-11 |
20210346475 | IMMUNIZATION WITH POLYVALENT VENOM VACCINES - This disclosure relates to materials and methods useful for vaccinating mammals against the effects of envenomation by venomous organisms (including the Western Rattlesnake) by making use of venom from multiple distinct populations, subspecies or species of the organism, to make a vaccine more broadly protective against other populations, subspecies or species. | 2021-11-11 |
20210346476 | Modified FVIII Apitope Peptides - The present invention provides peptides partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides peptides comprising the sequence DNIMVTFRNQASRPY or PRCLTRYYSSFVNME with modifications at the N- and C-termini. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia. | 2021-11-11 |
20210346477 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES - The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells. | 2021-11-11 |
20210346478 | NANO-SATELLITE COMPLEXES - The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles. In some embodiments, administration of the nanosatellite complexes to a subject with cancer achieves long-term cancer remission (e.g., when combined with an immune checkpoint inhibitor, such as αPD1). | 2021-11-11 |
20210346479 | THERAPEUTIC CANCER VACCINES DERIVED FROM A NOVEL DENDRITIC CELL LINE - The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012. | 2021-11-11 |
20210346480 | BREAST AND OVARIAN CANCER VACCINES - The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof. | 2021-11-11 |
20210346481 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-11-11 |
20210346482 | SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION - Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. In an exemplary embodiment of a noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy of the present disclosure, the method comprises the steps of withdrawing at least one biological sample from a cardiac allograft recipient; and analyzing the at least one biological sample for one or more biomarkers indicative of the presence of fibrin deposits within the cardiac allograft microvasculature; wherein detection of the one or more biomarkers indicates that the cardiac allograft recipient is at-risk for or developing cardiac allograft vasculopathy. | 2021-11-11 |
20210346483 | Combination Vaccine Composition Comprising Reduced Dose Inactivated Poliovirus And Method For Preparing The Same - The present disclosure relates to a fully liquid immunogenic composition comprising a combination of antigens/immunogens. The immunogenic composition comprises optimum amount of antigens/immunogens to confer protection against a number of diseases. The composition exhibits improved immunogenicity and stability. A process for preparing the vaccine composition is also disclosed. | 2021-11-11 |
20210346484 | METHOD OF PRODUCING A VACCINE COMPOSITION AND USES THEREOF - The present invention provides a method of producing a vaccine composition for the treatment of cancer comprising a fusion protein of at least two peptide sequences, the method comprising: (a) generating a library of peptide sequences; (b) obtaining at least one antibody that binds to an antigen associated with cancer or a checkpoint antigen; (c) screening the library generated in step (a) with the at least one antibody of step (b) to identify at least two peptide sequences that specifically bind to the at least one antibody; and (d) combining at least two of the peptide sequences identified in step (c) to produce a fusion protein, wherein the fusion protein, when administered to a subject, induces an antibody response directed against the antigen associated with cancer or the checkpoint antigen. | 2021-11-11 |
20210346485 | METHODS OF TREATING CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE - The present disclosure provides methods, uses, and kits for treating cancer in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-1 or anti-PD-L1 antibody) and an RNA vaccine (e.g., a personalized cancer vaccine that comprises one or more polynucleotides encoding one or more neoepitopes resulting from cancer-specific somatic mutations present in a tumor specimen obtained from the individual). Further provided herein are RNA molecules (e.g., a personalized RNA cancer vaccine that comprises one or more polynucleotides encoding one or more neoepitopes resulting from cancer-specific somatic mutations present in a tumor specimen obtained from the individual), as well as DNA molecules and methods useful for production or use of RNA vaccines. | 2021-11-11 |
20210346486 | COMBINATION CELL-BASED THERAPIES - The present disclosure provides methods of treatment with cells having a vaccine (e.g., gp96-Ig) and cells having a T-cell co-stimulatory molecule. | 2021-11-11 |
20210346487 | MULTIVALENT PNEUMOCOCCAL VACCINES - Technologies for the prevention and/or treatment of pneumococcal infections. | 2021-11-11 |
20210346488 | PURIFIED CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE - The invention relates to capsular polysaccharides of | 2021-11-11 |
20210346489 | VECTOR PRODUCTION - An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell. | 2021-11-11 |
20210346490 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE - The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation. | 2021-11-11 |
20210346491 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME - The present disclosure provides a method for the treatment or prophylaxis of coronavirus infection, comprising administering a therapeutically effective amount of an immunomodulator to a subject in need thereof or at risk of coronavirus infection. A vaccine composition comprising a pharmaceutically effective amount of an immunomodulator is also provided. | 2021-11-11 |
20210346492 | SARS-CoV-2 Vaccines - RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons. | 2021-11-11 |
20210346493 | SARS-COV-2 Antigen Polypeptide, Recombinant Adeno-Associated Virus Expressing the Polypeptide, and Vaccine Containing the Virus - Disclosed are a SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus (rAAV) expressing the polypeptide, and a vaccine containing the virus. A sequence of the antigen polypeptide is shown in SEQ NO. 1. and SEQ ID NO. 2. A method for preparing the recombinant adeno-associated virus comprises co-incubating pHelper, pRep2Cap5, and an expression vector, transfecting a cell in the presence of polyethyleneimine as a transfection reagent; culturing the cell, then collecting the cell by centrifugation, performing lysis and purification to obtain a purified liquid comprising the recombinant adeno-associated virus. The rAAV is delivered and expressed in vivo to produce a fusion antigen polypeptide, induces the production of serum neutralizing antibodies, which have a neutralizing titer to the novel SARS-COV-2 coronavirus and are expressed continuously; the rAAV composition can be used to immunize humans against the novel coronavirus pneumonia COVID-19. | 2021-11-11 |
20210346494 | MODIFIED CMV GB PROTEIN AND CMV VACCINE INCLUDING SAME - The present invention is directed to provide a modified CMV gB protein that can induce a group of antibodies including a high ratio of neutralizing antibodies that exhibit a high neutralizing activity against a CMV gB protein, in comparison with a wild type CMV gB, upon induction of immunity and that can be used in the prevention and/or treatment of CMV infection and a CMV vaccine comprising the modified CMV gB protein. The modified CMV gB protein according to the present invention is a modified CMV gB protein having an improved ability to induce body region-recognizing antibodies and comprising modification in a head region. | 2021-11-11 |
20210346495 | METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT - The current disclosure describes the use of NFkB inhibitors as immune potentiators in vaccine compositions comprising adjuvants. Accordingly, aspects of the disclosure relate to a method for vaccinating a subject comprising administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Further aspects relate to a method for inhibiting an inflammatory reaction associated with an adjuvant in a subject, the method comprising co-administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Yet further aspects relate to a pharmaceutical composition comprising a NFkB inhibitor and an adjuvant. | 2021-11-11 |
20210346496 | CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE - The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating diseases in a mammal utilizing the vaccine compositions. | 2021-11-11 |
20210346497 | Methods of Treating Cancer - This invention relates to new methods for treating cancer, including cancers characterized by expression of programmed death ligand 1 (PD-L1). | 2021-11-11 |
20210346498 | COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES - The invention provides a method of treating a patient having target cells that express FcγRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcγRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcγRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcγRIIb. | 2021-11-11 |
20210346499 | NANOPARTICLE DELIVERY SYSTEM FOR TARGETED ANTI-OBESITY TREATMENT - A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field. | 2021-11-11 |
20210346500 | PHOTOOXIDATIVE INACTIVATION OF PATHOGENS INCLUDING SARS-CoV-2 - Disclosed in certain embodiments is a method of treating a pathogenic infection comprising (i) contacting a pathogen residing in the oral cavity and/or pharynx of a patient in need thereof with a photosensitizer and (ii) subjecting the photosensitizer contacted pathogen to a light source. | 2021-11-11 |
20210346501 | ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS - Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. | 2021-11-11 |
20210346502 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES - The present disclosure relates to processes for preparing functionalized cyclooctenes and the synthetic intermediates prepared thereby. | 2021-11-11 |
20210346503 | COLON CLEANSING COMPOSITIONS AND METHOD OF USE - The invention provides a colon cleansing solution comprising: | 2021-11-11 |
20210346504 | Exosomes For Delivery Of Biotherapeutics - The present invention relates to exosomes, loaded with biotherapeutic protein and/or peptide and methods of producing them and to the use of such exosomes for delivering protein and/or peptide in vivo, in particular the use of such exosomes in methods of therapy. | 2021-11-11 |
20210346506 | PRODRUG OF ITRACONAZOLE AND USES THEREOF - The present invention relates to itraconazole prodrugs, pharmaceutical compositions comprising the prodrugs, and methods for treatment and/or prophylaxis of lung fibrosis, renal fibrosis, or liver fibrosis using the pharmaceutical compositions. | 2021-11-11 |
20210346507 | GEMCITABINE PRODRUGS - Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer. | 2021-11-11 |
20210346508 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE - Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ≥3.9 when administered at the same toxin dose. | 2021-11-11 |
20210346509 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof - The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor. | 2021-11-11 |
20210346510 | Tetravalent Antibody-Drug Conjugates and Use Thereof - An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided. | 2021-11-11 |
20210346511 | IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 2021-11-11 |
20210346512 | LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lymphoma, myeloma, leukemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer, for monitoring the effectiveness of cancer, such as lymphoma, myeloma, leukemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer treatment, and for drug development. | 2021-11-11 |
20210346513 | METHOD OF CONJUGATION OF CYS-MABS - The present disclosure relates to a method of capping, reducing, and oxidizing cys-mAbs in order to provide homogenous material for subsequent conjugation reactions. The present method demonstrates robust ways to manufacture conjugates of cysteine-engineered antibodies that offer high yield and consistent product quality. | 2021-11-11 |
20210346514 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process. | 2021-11-11 |
20210346515 | Materials and Methods for Inducing Therapeutic Hypothermia in a Mammalian Subject - Described herein are materials and methods for inducing therapeutic hypothermia in a subject in need thereof. | 2021-11-11 |
20210346516 | NANOHYDROXYAPATITE NANOCARRIER FOR GENETIC CARGO - The disclosure is directed to nanoparticles, compositions comprising nanoparticles, and methods of using the nanoparticles and compositions to introduce genetic material into a host cell, and in particular, a plant cell nucleus, to cause transformation of the host cell through the expression of genes on the introduced genetic material. | 2021-11-11 |
20210346517 | NANOPARTICLE PHARMACEUTICAL DELIVERY SYSTEM - A method of preparing a nanoparticle pharmaceutical delivery system. A nanoparticle pharmaceutical delivery system. A method of preparing a targeted nanoparticle pharmaceutical delivery system. A targeted nanoparticle pharmaceutical delivery system. | 2021-11-11 |
20210346518 | CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER - The present invention provides a cyanine modified telodendrimer, nanoparticles thereof, and methods of using the nanoparticles to treat various diseases such as cancer. | 2021-11-11 |
20210346519 | HYBRID REGULATORY ELEMENTS - The present invention relates to hybrid transcription regulatory elements to drive gene expression, in particular hybrid promoters, designed by the fusion of at least two transcription regulatory elements with different tissue selectivity, such as two promoters driving expression in different tissues in a tissue-selective manner. | 2021-11-11 |
20210346520 | METHODS OF USING INTRAVENOUS REXIN-G: A TUMOR-TARGETED RETROVECTOR ENCODING A DOMINANT-NEGATIVE CYCLIN G1 (CCNG1) INHIBITOR FOR ADVANCED PANCREATIC CANCER - The present disclosure teaches methods of treating a patient who has an advanced metastatic cancer, after the patient has the patient has failed at least one treatment regimen for the advanced metastatic cancer, by administering a plurality of infusions of a vector comprising a tumor signature-targeting peptide and a nucleic acid that encodes a dominant negative human cyclin G1 construct. One or more of the patient's treatment regimens may have included gemcitabine. The present disclosure also provides methods of treatment by further administering to the patient an additional therapeutic agent such as an immune-modulatory monoclonal antibody, a cytotoxic chemotherapeutic agent, an anti-angiogenesis agent, a selective tyrosine kinase inhibitor, or a monoclonal antibody directed against specific features of cells from the metastatic cancer. | 2021-11-11 |
20210346521 | GENE THERAPY VECTORS FOR TREATING HEART DISEASE - The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin T promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease. | 2021-11-11 |
20210346522 | Methods for determining cell killing by a human therapeutic - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided. | 2021-11-11 |
20210346523 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF - The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders. | 2021-11-11 |
20210346524 | FUSOGENIC LIPOSOMES FOR SELECTIVE IMAGING OF TUMOR CELLS - A fusogenic liposome comprising a detectable agent and optionally a cytotoxic drug in its internal aqueous compartment or bound to the liposome membrane is provided, wherein said fusogenic liposome comprises a lipid bilayer comprising a plurality of lipid molecules having 14 to 24 carbon atoms, and at least one of said lipid molecules further comprises a cationic group, a cationic natural or synthetic polymer, a cationic amino sugar, a cationic polyamino acid or an amphiphilic cancer-cell binding peptide; and at least one of said lipid molecules further comprises a stabilizing moiety selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone (PVP), dextran, a polyamino acid, methyl-polyoxazoline, polyglycerol, poly(acryloyl morpholine), and polyacrylamide. Methods utilizing these liposomes in treatment of cancer are further provided. | 2021-11-11 |
20210346525 | COMPOSITION AND METHODS FOR TUMOR IMAGING AND TREATMENT - Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment. | 2021-11-11 |
20210346526 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION - The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof. | 2021-11-11 |
20210346527 | Combination Therapy - The present invention relates to combination therapies of radiolabelled somatostatin receptor binding compounds with PARR inhibitors. | 2021-11-11 |
20210346528 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer - The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods. | 2021-11-11 |
20210346529 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer - The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods. | 2021-11-11 |
20210346530 | STERILIZATION TOOL FOR DENTAL AND MEDICAL TOOLS AND RELATED SYSTEMS AND METHODS - A sterilization apparatus may include a cavity defined by walls of the apparatus. The sterilization apparatus may further include at least one internal compartment within the cavity. The internal compartment may include at least one reflective surface. The sterilization apparatus may also include one or more ultraviolet lights on a surface of at least one of the walls of the apparatus and directed toward the at least one internal compartment. The one or more ultraviolet lights may be configured to produce ultraviolet light in one or more of the UVB and UVC spectrums. | 2021-11-11 |
20210346531 | ANTIVIRAL AND ANTIBACTERIAL DISINFECTION AERO-SOLUTION USING EDIBLE FOOD DYES - A whole-body or whole-room voluminous antiviral and antibacterial airborne disinfection system is disclosed which includes a sterilization chamber, including a nozzle disposed in the sterilization chamber, a tank disposed outside the sterilization chamber, the tank is adapted to hold a photosensitizer fluid of edible food dyes, a light source within the sterilization chamber adapted to flood the sterilization chamber with light; and a nozzle adapted to release the photosensitizer fluid aerosols and generate reactive oxygen species in a fog-like dispersion. | 2021-11-11 |
20210346532 | System and Sanitizable Hardware for Detecting Pathogens on Hands - The mechanical and system design of a device to detect pathogens on hands including means to sanitize the device while protecting the user from said sanitizer emissions be they optical, gaseous or liquid. | 2021-11-11 |
20210346533 | Reprocessing of Medical Devices that Are Contaminated with Bacteria, Viruses, Other Pathogens, and Biofilms with Shockwaves, Pressure Waves or Ultrasound Systems - A reusable apparatus, such as a medical instrument or tool, is decontaminated by applying at least one of pressure waves, shockwaves, and ultrasound waves in a sufficient dosage to remove contamination but without adversely affecting the ability to reuse the apparatus. | 2021-11-11 |
20210346534 | SYSTEM AND METHOD FOR SANITIZING CURRENCY - A system and method for sanitizing currency is provided. The system generally comprises a container, control board, switch, power supply, heating elements, temperature probe, and charging ports. Currency is inserted into the system via an entrance, and the control board provides power to the heating elements from the power supply to increase the temperature within the internal cavity of the container. The temperature probe assists the control board and heating element to maintain a desired temperature for a desired length of time in order to kill pathogens that may be living on the currency. A switch on the container may be used to complete a circuit of control board and initiate a cleaning cycle when the entrance is closed by a user. | 2021-11-11 |
20210346535 | Anti-Viral Dry Cleaning Process - Provided herein is a method of treating material that is contaminated with a virus, comprising exposing the material to vapor, wherein the vapor is produced by heating and/or vaporizing a dry cleaning solvent, and wherein the method at least partially deactivates the virus. | 2021-11-11 |
20210346536 | MOBILE STERILIZATION APPARATUS AND METHOD FOR USING THE SAME - A sterilization cabinet, comprising a top panel, at least two side panels, and a floor panel forming a part of a chamber of the sterilization cabinet; at least one door connected to at least one of the at least two side panels of the sterilization cabinet; a vent formed in at least one of the two side panels; at least one first filter covering the vent and a filter cover configured to hold the first filter against the vent; a drain positioned in the floor panel, wherein the floor panel has a slope configured to cause condensate within the chamber to flow into the drain and wherein the drain is the only outlet for the condensate along the floor panel; and a second filter covering the drain such that condensate flowing into the drain passes through the second filter. | 2021-11-11 |
20210346537 | SANITIZER FOR COSMETICS - An applicator wand for the cosmetic product is optically coupled to an ultraviolet light source as an illumination source of ultraviolet light wavelengths. The applicator wand provides the source of the ultraviolet light wavelengths to be a germicide for bacteria in the cosmetic product on the applicator wand. The ultraviolet light source emits the ultraviolet light wavelengths in a range extending between 202-225 nm. A container contains the cosmetic product. The cap of the container attaches to a body of the container. One or more batteries electrically connect to at least an electronic control circuit and the ultraviolet light source. | 2021-11-11 |
20210346538 | CURRENCY SANITIZER - One of the most common surfaces handled by a multitude of persons, without intermediate cleansing, is money. Viruses, bacteria, germs, and any other infectious elements that may cause disease, are generally transmitted via contact with a person who is infected or has recently touched a person or surface which has been thus contaminated. This invention fulfills society's need for money handlers to sanitize previously contaminated currency before they themselves become infected. The invented device may also be used by the money handler to sanitize currency before making change and giving it to another customer. This cycle may be interrupted and thereby reducing the spread of communicable diseases. | 2021-11-11 |
20210346539 | PORTABLE SANITIZING SYSTEMS AND METHODS - A portable sanitizing system and method includes a sanitizing head including an ultraviolet (UV) lamp. The UV lamp is configured to emit UV light having a wavelength between 200 nm-230 nm to disinfect a surface. | 2021-11-11 |